1
|
Ricordel C, Chaillot L, Vlachavas EI, Logotheti M, Jouannic A, Desvallees T, Lecuyer G, Aubry M, Kontogianni G, Mastrokalou C, Jouan F, Jarry U, Corre R, Le Guen Y, Guillaudeux T, Lena H, Chatziioannou A, Pedeux R. Genomic characteristics and clinical significance of CD56+ circulating tumor cells in small cell lung cancer. Sci Rep 2023; 13:3626. [PMID: 36869231 PMCID: PMC9984363 DOI: 10.1038/s41598-023-30536-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 02/24/2023] [Indexed: 03/05/2023] Open
Abstract
Circulating tumor cells (CTC) have been studied in various solid tumors but clinical utility of CTC in small cell lung cancer (SCLC) remains unclear. The aim of the CTC-CPC study was to develop an EpCAM-independent CTC isolation method allowing isolation of a broader range of living CTC from SCLC and decipher their genomic and biological characteristics. CTC-CPC is a monocentric prospective non-interventional study including treatment-naïve newly diagnosed SCLC. CD56+ CTC were isolated from whole blood samples, at diagnosis and relapse after first-line treatment and submitted to whole-exome-sequencing (WES). Phenotypic study confirms tumor lineage and tumorigenic properties of isolated cells for the 4 patients analyzed with WES. WES of CD56+ CTC and matched tumor biopsy reveal genomic alteration frequently impaired in SCLC. At diagnosis CD56+ CTC were characterized by a high mutation load, a distinct mutational profile and a unique genomic signature, compared to match tumors biopsies. In addition to classical pathways altered in SCLC, we found new biological processes specifically affected in CD56+ CTC at diagnosis. High numeration of CD56+ CTC (> 7/ml) at diagnosis was associated with ES-SCLC. Comparing CD56+ CTC isolated at diagnosis and relapse, we identify differentially altered oncogenic pathways (e.g. DLL3 or MAPK pathway). We report a versatile method of CD56+ CTC detection in SCLC. Numeration of CD56+ CTC at diagnosis is correlated with disease extension. Isolated CD56+ CTC are tumorigenic and show a distinct mutational profile. We report a minimal gene set as a unique signature of CD56+ CTC and identify new affected biological pathways enriched in EpCAM-independent isolated CTC in SCLC.
Collapse
Affiliation(s)
- Charles Ricordel
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France.
- Service de Pneumologie, Hôpital Pontchaillou, CHU Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.
| | - L Chaillot
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
| | - E I Vlachavas
- e-NIOS PC, Kallithea-Athens, Greece
- Division of Molecular Genome Analysis (B050), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
| | | | - A Jouannic
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
| | - T Desvallees
- CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Univ Rennes, 35000, Rennes, France
- Unité De Pharmacologie Préclinique, Biotrial Pharmacology, Rennes, France
| | - G Lecuyer
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
| | - M Aubry
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
| | - G Kontogianni
- Centre of Systems Biology, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 11527, Athens, Greece
| | | | - F Jouan
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
| | - U Jarry
- CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Univ Rennes, 35000, Rennes, France
- Unité De Pharmacologie Préclinique, Biotrial Pharmacology, Rennes, France
| | - R Corre
- Service de Pneumologie, Hôpital Pontchaillou, CHU Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France
| | - Y Le Guen
- Service de Pneumologie, Hôpital Pontchaillou, CHU Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France
| | - T Guillaudeux
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
- CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Univ Rennes, 35000, Rennes, France
| | - H Lena
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France
- Service de Pneumologie, Hôpital Pontchaillou, CHU Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France
| | - A Chatziioannou
- e-NIOS PC, Kallithea-Athens, Greece
- Centre of Systems Biology, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 11527, Athens, Greece
| | - Rémy Pedeux
- INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Univ Rennes 1, 35000, Rennes, France.
- CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Univ Rennes, 35000, Rennes, France.
- CLCC Eugène Marquis, INSERM U1242-OSS, Université Rennes 1, Rue Bataille Flandres Dunkerque, 35042, Rennes, France.
| |
Collapse
|
2
|
Cho B, Ahn MJ, Kim T, Kim C, Shim B, Han JY, Drilon A, Lena H, Gomez J, Gray J, Awad M, Perez J, Navas M, Kaul M, Patel S, Gao B, Magnan H, Rietschel P. 1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Johnson M, de Langen A, Waterhouse D, Mazieres J, Dingemans AM, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Okamoto I, Kim SW, Linardou H, Novello S, Chen Y, Solomon B, Obiozor C, Wang Y, Paz-Ares L. LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.051] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
4
|
Girard N, Mazieres J, Otto J, Lena H, Lepage C, Egenod T, Smith D, Madelaine J, Gérinière L, El Hajbi F, Ferru A, Clément-Duchêne C, Madroszyk A, Desrame J, Morin F, Langlais A, Michel P, Louvet C, Westeel V, Walter T. LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2119] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
5
|
Pérol M, Quantin X, Lena H, Filleron T, Chouaid C, Valette CA, Kaderbhai C, Chenuc G, Santorelli M, Bensimon L, Burke T, Simon G, Martin AL, Debieuvre D, Gervais R, Schott R, Carton M, Courtinard C, Girard N. 110P Real-world evaluation of pembrolizumab monotherapy for previously treated PD-L1 positive (TPS>1%) advanced NSCLC in France. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01952-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
6
|
Pierre C, Goter T, Agar C, Luzi S, Lena H, Guen YL, Ricordel C. 179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center. J Thorac Oncol 2021. [PMCID: PMC7997779 DOI: 10.1016/s1556-0864(21)02021-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Pérol M, Filleron T, Quantin X, Chouaid C, Valette CA, Lena H, Kaderbhai C, Fabre C, Santorelli M, Bensimon L, Burke T, Couch D, Nguyen E, Courtinard C. 109P Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01951-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Monnet I, Vergnenegre A, Robinet G, Berard H, Lamy R, Falchero L, S. vieillot, Schott R, Lena H, Chouabe S, Thomas P, Gervais R, Flandin ACM, Abdiche S, Chiappa AM, Greillier L, Decroisette C, Auliac J, Chouaid C. 1306P Platin pemetrexed with or without bevacizumab with upfront versus “at progression” brain radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis: A randomized phase III trial (Metal2 trial). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
9
|
Le Tallec E, Belhomme N, Lena H, Ballerie A, Lescoat A, Jego P. Fasciite de Shulman et cholangite induites par un anti-PD-1. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR. Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. Ann Oncol 2019; 29:1548-1553. [PMID: 29767677 DOI: 10.1093/annonc/mdy177] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Bavituximab is a monoclonal antibody that targets phosphatidylserine in the presence of β2 glycoprotein 1 (β2GP1) to exert an antitumor immune response. This phase III trial determined the efficacy of bavituximab combined with docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). Patients and methods Key eligibility criteria included advanced non-squamous NSCLC with disease progression after treatment with platinum-based doublet chemotherapy, evidence of disease control after at least two cycles of first-line therapy, presence of measurable disease, ECOG performance status 0 or 1, adequate bone marrow and organ function, and no recent history of clinically significant bleeding. Eligible patients were randomized 1 : 1 to receive up to six 21-day cycles of docetaxel plus either weekly bavituximab 3 mg/kg or placebo until progression or toxicity. The primary end point was overall survival (OS). Results A total of 597 patients were enrolled. Median OS was 10.5 months in the docetaxel + bavituximab arm and was 10.9 months in the docetaxel + placebo arm (HR 1.06; 95% CI 0.88-1.29; P = 0.533). There was no difference in progression-free survival (HR 1.00; 95% CI 0.82-1.22; P = 0.990). Toxicities were manageable and similar between arms. In subset analysis, among patients with high baseline serum β2GP1 levels ≥200 µg/ml, a nonsignificant OS trend favored the bavituximab arm (HR 0.82; 95% CI 0.63-1.06; P = 0.134). Among patients who received post-study immune checkpoint inhibitor therapy, OS favored the bavituximab arm (HR 0.46; 95% CI 0.26-0.81; P = 0.006). Conclusions The combination of bavituximab plus docetaxel is not superior to docetaxel in patients with previously treated advanced NSCLC. The addition of bavituximab to docetaxel does not meaningfully increase toxicity. The potential benefit of bavituximab observed in patients with high β2GP1 levels and in patients subsequently treated with immune checkpoint inhibitors requires further investigation. Clinical trial number NCT01999673.
Collapse
Affiliation(s)
- D E Gerber
- Division of Hematology-Oncology, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, USA.
| | - L Horn
- Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt-Ingram Cancer Center, Nashville, USA
| | - M Boyer
- Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia
| | - R Sanborn
- Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland; USA
| | - R Natale
- Department of Internal Medicine (Hematology-Oncology), Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA
| | - R Palmero
- Medical Oncology Service, Institut Català d'Oncologia -L'Hospitalet, Barcelona, Spain
| | - P Bidoli
- Department of Oncology, ASST di Monza - Azienda Ospedaliera San Gerardo, Monza, Italy
| | - I Bondarenko
- State Institution Dnipropetrovsk Medical, Academy of the Ministry of Health of Ukraine, Communal Institution Dnipropetrovsk City Multifield Clinical Hospital No. 4 of Dnipropetrovsk Regional Council, Dnipropetrovsk, Ukraine
| | - P Germonpre
- Department of Pneumology, AZ Maria Middelares, Gent, Belgium
| | - D Ghizdavescu
- Department of Oncology, Ploiesti Municipal Hospital, Ploiesti, Romania
| | - A Kotsakis
- Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece
| | - H Lena
- Pneumology Service, Hôspital Pontchaillou, Rennes, France
| | - G Losonczy
- Pulmonology Clinic, Semmelweis Egyetem, Budapest, Hungary
| | - K Park
- Division of Hematology-Oncology, Samsung Medical Center, Seoul, Korea
| | - W-C Su
- Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
| | - M Tang
- Peregrine Pharmaceuticals, Inc., Tustin, USA
| | - J Lai
- Peregrine Pharmaceuticals, Inc., Tustin, USA
| | | | - J S Shan
- Peregrine Pharmaceuticals, Inc., Tustin, USA
| | - M Reck
- Department of Thoracic Oncology, German Center for Lung research (DZL), Lungen Clinic Grosshansdorf, Grosshansdorf, Germany
| | - D R Spigel
- Lung Cancer Clinical Research Program, Sarah Canon Research Institute, Nashville, USA
| |
Collapse
|
11
|
Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac J, Le Treut J, Le Caer H, Gervais R, Dansin E, Madroszyk A, Renault P, Legarff G, Schott R, Saulnier P, Chouaid C. OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.490] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Girard N, Pérol M, Simon G, Audigier Valette C, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, Carton M, Robain M, Filleron T, Chouaid C. Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz067.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Wislez M, Blons H, Domblides C, Barlesi F, Mazieres J, Monnet I, Kiakouama Maleka L, Quantin X, Taillade L, Lena H, Fraisse P, Janicot H, Audigier Valette C, Amour E, Langlais A, Rabbe N, Cadranel J, Laurent puig P, Lavolé A. Circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): Results from phase II trial (IFCT-1001 CHIVA). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Palmero R, Bidoli P, Bondarenko I, Boyer M, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Reck M, Su WC, Kallinteris N, Tang M, Lai J, Shan J, Spigel D. Final clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.065] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Besse B, Mazières J, Ribassin-Majed L, Barlesi F, Bennouna J, Gervais R, Moreau L, Berard H, Debieuvre D, Molinier O, Moro-Sibilot D, Souquet P, Jacquot S, Petit L, Lena H, Pignon J, Lacas B, Morin F, Milleron B, Zalcman G, Soria J. Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial. Ann Oncol 2017; 28:1078-1083. [DOI: 10.1093/annonc/mdx070] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Chouaid C, Auliac JB, Chouahnia K, Decroisette C, Le Garff G, Lena H, Audigier-Valette C, vaylet F, Perol D, Varea R, Nacerddine K, D’yachkova Y, Chartier F, Uruñuela A, Winfree KB, Rassam HN, Visseren-Grul C, Moro Sibilot D. Étude en vie réelle de l’usage du pémétrexed en France. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
17
|
Barlesi F, Dingemans AM, Yang JH, Ou SH, Ahn J, De Petris L, Hughes B, Lena H, Bordogna W, Golding S, Morcos P, Balas B, Zeaiter A, Kim DW. Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.63] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Jaksic N, Colliaux J, Castelli J, Lena H, Bellec J, Kerjouan M, Devillers A, Ricordel C, de Latour B, de Crevoisier R, Chajon E. La réponse tumorale précoce évaluée sur tomographie conique au cours de la radiothérapie est prédictive du pronostic des cancers bronchiques non à petites cellules localement évolués. Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.08.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
19
|
Ferolla P, Brizzi M, Meyer T, Mansoor W, Mazieres J, Cao C, Lena H, Berruti A, Damiano V, Buikhuisen W, Stankovic M, Singh N, Chiodini E, Gislimberti G, Oberg K, Baudin E. Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw369.01] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Bluthgen M, Dansin E, Ou D, Lena H, Mazieres J, Pichon E, Thillays F, Massard G, Quantin X, Oulkhouir Y, Hon TNT, Thiberville L, Clement-Duchene C, Lindsay C, Missy P, Molina T, Girard N, Besse B, Thomas P. Quality of resection and outcome in stage III thymic epithelial tumors (TET): A retrospective analysis of 150 cases from the national network RYTHMIC experience. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw391.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Gauvain C, Lena H, Corre R, Ricordel C, Vinas F, Chouaid C. Immunothérapie : un nouveau paradigme dans la prise en charge du cancer bronchique non à petites cellules. ONCOLOGIE 2016. [DOI: 10.1007/s10269-016-2633-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
22
|
Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol 2016; 27:1291-8. [PMID: 27117531 DOI: 10.1093/annonc/mdw174] [Citation(s) in RCA: 101] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2015] [Accepted: 04/04/2016] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND In the phase I KEYNOTE-001 study, pembrolizumab demonstrated durable antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC). We sought to characterize the relationship between pembrolizumab dose, exposure, and response to define an effective dose for these patients. PATIENTS AND METHODS Patients received pembrolizumab 2 mg/kg every 3 weeks (Q3W) (n = 55), 10 mg/kg Q3W (n = 238), or 10 mg/kg Q2W (n = 156). Response (RECIST v1.1) was assessed every 9 weeks. The relationship between the estimated pembrolizumab area under the concentration-time curve at steady state over 6 weeks (AUCss-6weeks) and the longitudinal change in tumor size (sum of longest diameters) was analyzed by regression and non-linear mixed effects modeling. This model was simultaneously fit to all tumor size data, then used to simulate response rates, normalizing the trial data across dose for prognostic covariates (tumor PD-L1 expression and EGFR mutation status). The exposure-safety relationship was assessed by logistic regression of pembrolizumab AUCss-6weeks versus occurrence of adverse events (AEs) of interest based on their immune etiology. RESULTS Overall response rates were 15% [95% confidence interval (CI) 7%-28%] at 2 mg/kg Q3W, 25% (18%-33%) at 10 mg/kg Q3W, and 21% (95% CI 14%-30%) at 10 mg/kg Q2W. Regression analyses of percentage change from baseline in tumor size versus AUCss-6weeks indicated a flat relationship (regression slope P > 0.05). Simulations showed the exposure-response relationship to be similarly flat, thus indicating that the lowest evaluated dose of 2 mg/kg Q3W to likely be at or near the efficacy plateau. Exposure-safety analysis showed the AE incidence to be similar among the clinically tested doses. CONCLUSIONS No significant exposure dependency on efficacy or safety was identified for pembrolizumab across doses of 2-10 mg/kg. These results support the use of a 2 mg/kg Q3W dosage in patients with previously treated, advanced NSCLC. CLINICALTRIALSGOV REGISTRY NCT01295827.
Collapse
Affiliation(s)
- M Chatterjee
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA
| | - D C Turner
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA
| | - E Felip
- Thoracic Tumors Group, Vall d'Hebron University Hospital, Barcelona, Spain
| | - H Lena
- Pneumonology Service, Centre Hospitalier Universitaire Rennes, Rennes, France
| | - F Cappuzzo
- Department of Medical Oncology, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy
| | - L Horn
- Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, USA
| | - E B Garon
- Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, USA
| | - R Hui
- Department of Medical Oncology, Westmead Hospital and the University of Sydney, Sydney, Australia
| | - H-T Arkenau
- Department of Medical Oncology, Sarah Cannon Research Institute UK and University College London, London, UK
| | - M A Gubens
- Department of Medicine, University of California, San Francisco, San Francisco
| | - M D Hellmann
- Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York
| | - D Dong
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA
| | - C Li
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA
| | - K Mayawala
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA
| | - T Freshwater
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA
| | - M Ahamadi
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA
| | - J Stone
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA
| | - G M Lubiniecki
- Oncology Clinical Research, Merck & Co., Inc., Kenilworth
| | - J Zhang
- Biostatistics and Research Design Sciences, Merck & Co., Inc., Kenilworth, USA
| | - E Im
- Oncology Clinical Research, Merck & Co., Inc., Kenilworth
| | - D P De Alwis
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA
| | - A G Kondic
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA
| | - Ø Fløtten
- Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway
| |
Collapse
|
23
|
Lena H, Rizvi N, Wolf J, Cappuzzo F, Zalcman G, Baas P, Mazieres J, Farsaci B, Blackwood-Chirchir M, Ramalingam S. 137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30247-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Lena H, Do P, Dansin E, Robinet G, Veillon R, Fayette J, Mazières J, Bennouna J, Coudert B, Barlési F, Morot-Sibilot D. Données d’efficacité et de tolérance d’un essai de phase 2 international, en ouvert, à un bras d’alectinib (NP28673), chez des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) ALK+ en échec au crizotinib. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Raynaud C, Greillier L, Mazieres J, Monnet I, Mastroianni B, Robinet G, Fraboulet G, Dixmier A, Berard H, Lamy R, Letreut J, Lena H, Oliviero G, Botta S, Vergnenegre A, Borget I, Chouaid C. Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). BMC Cancer 2015; 15:857. [PMID: 26546402 PMCID: PMC4635998 DOI: 10.1186/s12885-015-1881-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2015] [Accepted: 10/30/2015] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Malignant pleural mesothelioma (MPM) is a rare disease with poor prognosis in spite of significant improvement in survival, due to new chemotherapy regimens. We describe here patients' profiles and management in daily practice in France. METHODS Observational retrospective study. Data were collected from medical files. All patients with histologically proven MPM diagnosed from January 2005 to December 2008 were included in the participating sites. RESULTS Four hundred and six patients were included in 37 sites: mean age 68.9 ± 9.8 years, male predominance (sex ratio 3.27), latency of the disease 45.7 years, epithelioïd type 83 %. Diagnosis was made using thoracoscopy in 80.8 % of patients. Radical surgery was performed in 6.2 % of cases. Chemotherapy was administered to 74.6 % of patients. First line regimens consisted mainly of platinum + pemetrexed (91 %) or pemetrexed alone (7 %). Objective response rate was 17.2 % and another 41.6 % of patients experienced disease stabilization. Half of these patients underwent second line chemotherapy (platinium + pemetrexed 31.6 %, pemetrexed alone 24.6 %), resulting in a 6 % response rate. Third-line chemotherapy (56 patients) yielded disease control in 5.4 % of cases. CONCLUSIONS The management of MPM in France is usually in accordance with guidelines. Response rates are somewhat lower than those described in clinical trials.
Collapse
Affiliation(s)
- C Raynaud
- Service de Pneumologie, CH Argenteuil, Argenteuil, France.
| | - L Greillier
- Service d'oncologie thoracique, APHM, Marseille, Services de Pneumologie, Marseille, France.
| | | | - I Monnet
- Service de pneumologie, CHI Créteil, 40 avenue de verdun, 94010, Créteil, France.
| | | | | | | | | | | | - R Lamy
- CH Lorient, Lorient, France.
| | - J Letreut
- CH Aix en Provence, Aix en Provence, France.
| | - H Lena
- CHU Rennes, Rennes, France.
| | | | | | | | | | - C Chouaid
- Service de pneumologie, CHI Créteil, 40 avenue de verdun, 94010, Créteil, France.
| |
Collapse
|
26
|
Barlesi F, Dingemans A, Ou I, Ahn J, Petris L, Kim D, Yang J, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Viteri S, Mekhail T, Spira A, Zeaiter A, Bordogna W, Sturm C, Golding S, Morcos P, Govindan R. 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31742-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Cadranel J, Quoix E, Duruisseaux M, Friard S, Fabre E, Daniel C, Westeel V, Madroszyk A, Lena H, Merle P, Mazieres J, Dansin E, Scherpereel A, Hiret S, Coudert B, Souquet P, Missy P, Morin F, Zalcman G, Barlesi F. 3128 EGFR, ALK, KRAS prognostic value in a large French prospective cohort of non-previously treated advanced NSCLC. Preliminary report of the IFCT-PREDICT.amm cohort. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31769-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
28
|
Vansteenkiste J, Barlesi F, Waller CF, Bennouna J, Gridelli C, Goekkurt E, Verhoeven D, Szczesna A, Feurer M, Milanowski J, Germonpre P, Lena H, Atanackovic D, Krzakowski M, Hicking C, Straub J, Picard M, Schuette W, O'Byrne K. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Ann Oncol 2015; 26:1734-40. [PMID: 25939894 DOI: 10.1093/annonc/mdv219] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2015] [Accepted: 04/28/2015] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab and chemotherapy alone, as first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients were randomized 1:1:1 to receive cetuximab plus platinum-based chemotherapy alone (control), or combined with cilengitide 2000 mg 1×/week i.v. (CIL-once) or 2×/week i.v. (CIL-twice). A protocol amendment limited enrolment to patients with epidermal growth factor receptor (EGFR) histoscore ≥200 and closed the CIL-twice arm for practical feasibility issues. Primary end point was progression-free survival (PFS; independent read); secondary end points included overall survival (OS), safety, and biomarker analyses. A comparison between the CIL-once and control arms is reported, both for the total cohorts, as well as for patients with EGFR histoscore ≥200. RESULTS There were 85 patients in the CIL-once group and 84 in the control group. The PFS (independent read) was 6.2 versus 5.0 months for CIL-once versus control [hazard ratio (HR) 0.72; P = 0.085]; for patients with EGFR histoscore ≥200, PFS was 6.8 versus 5.6 months, respectively (HR 0.57; P = 0.0446). Median OS was 13.6 for CIL-once versus 9.7 months for control (HR 0.81; P = 0.265). In patients with EGFR ≥200, OS was 13.2 versus 11.8 months, respectively (HR 0.95; P = 0.855). No major differences in adverse events between CIL-once and control were reported; nausea (59% versus 56%, respectively) and neutropenia (54% versus 46%, respectively) were the most frequent. There was no increased incidence of thromboembolic events or haemorrhage in cilengitide-treated patients. αvβ3 and αvβ5 expression was neither a predictive nor a prognostic indicator. CONCLUSIONS The addition of cilengitide to cetuximab/chemotherapy indicated potential clinical activity, with a trend for PFS difference in the independent-read analysis. However, the observed inconsistencies across end points suggest additional investigations are required to substantiate a potential role of other integrin inhibitors in NSCLC treatment. CLINICAL TRIAL REGISTRATION ID NUMBER NCT00842712.
Collapse
Affiliation(s)
- J Vansteenkiste
- Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospitals KU Leuven, Leuven, Belgium
| | - F Barlesi
- Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University-Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - C F Waller
- Haematology, Oncology and Stem Cell Transplantation, University Hospital of Freiburg, Freiburg, Germany
| | - J Bennouna
- Département d'Oncologie Médicale, Centre Rene Gauducheau, Saint-Herblain Cedex, France
| | - C Gridelli
- Division of Medical Oncology, Azienda Ospedaliera 'S.G. Moscati', Avellino, Italy
| | - E Goekkurt
- Department of Oncology, Hematology, Stem Cell Transplantation and Hemostaseology, University Hospital Aachen, Aachen, Germany
| | - D Verhoeven
- Iridium Cancer Network, Medical Oncology, AZ Klina, Antwerp, Belgium
| | - A Szczesna
- Mazowieckie Centrum Leczenia Chorób Pluc i Gruźlicy, Otwock, Poland
| | - M Feurer
- Lungenpraxis Munich, Munich, Germany
| | - J Milanowski
- Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland
| | - P Germonpre
- Pulmonary Medicine, AZ Maria Middelares, Ghent, Belgium
| | - H Lena
- Pneumology, CHU Rennes, Rennes, France
| | - D Atanackovic
- Oncology/Hematology/Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Krzakowski
- The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Lung and Thoracic Tumours, Warsaw, Poland
| | | | | | | | - W Schuette
- Krankenhaus Martha-Maria Halle-Dölau, Klinik für Innere Medizin II, Halle, Germany
| | - K O'Byrne
- Cancer Services, Princess Alexandra Hospital, Brisbane, Australia
| |
Collapse
|
29
|
De Latour B, Guihaire J, Kerjouan M, Corre R, Rouze S, Lentz PA, Meunier C, Roisne A, Lena H, Flecher E, Verhoye JP. Place du robot en chirurgie thoracique : expérience rennaise initiale et revue de la littérature. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2015.04.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
30
|
Quoix E, Nemunaitis J, Papai Z, Lena H, Genet D, Louis C, Cobo M, Al Farhat Y, Marie-Bastien B, Limacher J. TG4010 Immunotherapy Combined with First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2B Results of the Time Study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv050.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Zalcman G, Rizvi N, Lena H, Wolf J, Mazieres J, Antonia S, Minenza E, Planchard D, Lestini B, Ramalingam S. Phase 2 Study of Nivolumab (ANTI-PROGRAMMED DEATH-1 [PD-1]) in Patients (PTS) with Advanced, Refractory Squamous (SQ) Non-Small Cell Lung Cancer (NSCLC). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv050.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Ricordel C, Labalette-Tiercin M, Guerillon C, Bigot N, Mouche A, Burel A, Lena H, Guillaudeux T, Pedeux R. Studying the function of mitochondrial ING2, a tumor suppressor protein frequently lost in non-small cell lung cancer. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2015.02.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Tiercin-Labalette M, Lespagnol A, Denis M, Le Gac G, Zalcman G, Bout J, Bizec JL, Marc M, Richard N, Lena H, Corre R. Octomut, étude observationnelle rétrospective multicentrique épidémiologique des patients de 80ans et plus avec un CBNPC muté EGFR et traités par EGFR-TKI. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.656] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Ramalingam S, Mazières J, Planchard D, Stinchcombe T, Dy G, Antonia S, Horn L, Lena H, Minenza E, Mennecier B, Otterson G, Campos L, Gandara D, Levy B, Nair S, Zalcman G, Wolf J, Baudelet C, Lestini B, Rizvi N. Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.09.038] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
35
|
Wakelee H, Zvirbule Z, De Braud F, Kingsley C, Mekhail T, Schütte W, Lena H, Lawler W, Braiteh F, Cosgriff T, Kaen D, Boyer M, Hsu J, Phan S, Novello S. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821). Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.08.216] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
36
|
Mazières J, Zalcman G, Crinò L, Biondani P, Filleron T, Dingemans A, Lena H, Monnet I, Rothschild S, Cappuzzo F, Thiberville L, Barlesi F, Dziadziuszko R, Smit E, Wolf J, Spirig C, Pecuchet N, Diebold J, Milia J, Gautschi O. Crizotinib in Patients with Lung Cancer and Ros1 Fusion: Results from the European Cohort Euros1. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.77] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Corre R, Chouaid C, Greillier L, Caer HL, Valette CA, Baize N, Berard H, Falchero L, Descourt R, Dansin E, Vergnenegre A, Bigay-Gamé L, Schott R, Garff GL, Treut JL, Sureda BM, Daures J, Plassot C, Lena H. Quality of Life Analysis of Esogia-Gfpc-Gecp Trial- a Phase Iii, Randomized, Multicenter Study Comparing in Elderly Patients (≥70 Years) with Stage Iv Nsclc a Treatment Allocation Based on Ps and Age with an Experimental Strategy According to a Comprehensive Geriatric Assessment (Cga). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Vansteenkiste J, Barlesi F, Waller C, Bennouna J, Gridelli C, Goekkurt E, Verhoeven D, Szczesna A, Feurer M, Milanowski J, Germonpre P, Lena H, Atanackovic D, Krzakowski M, Hicking C, Straub J, Picard M, Schuette W, Byrne KO. Cilengitide (Cil) Combined with Cetuximab and Platinum-Based Chemotherapy As First-Line Treatment in Advanced Non-Small Cell Lung Cancer (Nsclc) Patients (Pts): Phase Ii Randomised Certo Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de Las Peñas R, Karachaliou N, Sala MA, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez JJ, Camps C, Liu B, Rosell R, Colinet B, De Grève J, Germonpré P, Chen H, Chen X, Du J, Gao Y, Hu J, Hu W, Kong W, Li L, Li R, Li X, Liu B, Liu J, Lu H, Qian X, Ren W, Song Y, Wang L, Wei J, Wen L, Wu Q, Xiao X, Xu X, Yan J, Yang J, Yang M, Yang Y, Yin J, You C, Yu L, Yue X, Zhang F, Zhang J, Zhou Y, Zhu L, Zou Z, Baize N, Bombaron P, Chouaid C, Dansin E, Fournel P, Fraboulet G, Gervais R, Hominal S, Kahlout S, Lecaer H, Lena H, LeTreut J, Locher C, Molinier O, Monnet I, Oliviero G, Robinet G, Schoot R, Thomas P, Vergnènegre A, Berchem G, Rauh S, Al Husaini H, Aparisi F, Arriola E, Ballesteros I, Barneto I, Bernabé R, Blasco A, Bosch-Barrera J, Bover I, Calvo de Juan V, Camps C, Carcereny E, Catot S, Cobo M, De Las Peñas R, Dómine M, Felip E, García-Campelo MR, García-Girón C, García-Gómez R, Garcia-Sevila R, Garde J, Gasco A, Gil J, González-Larriba JL, Hernando-Polo S, Jantus E, Insa A, Isla D, Jiménez B, Lianes P, López-López R, López-Martín A, López-Vivanco G, Macias JA, Majem M, Marti-Ciriquian JL, Massuti B, Montoyo R, Morales-Espinosa D, Morán T, Moreno MA, Pallares C, Parera M, Pérez-Carrión R, Porta R, Provencio M, Reguart N, Rosell R, Rosillo F, Sala MA, Sanchez JM, Sullivan I, Terrasa J, Trigo JM, Valdivia J, Viñolas N, Viteri S, Botia-Castillo M, Mate JL, Perez-Cano M, Ramirez JL, Sanchez-Rodriguez B, Taron M, Tierno-Garcia M, Mijangos E, Ocaña J, Pereira E, Shao J, Sun X, O'Brate R. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann Oncol 2014; 25:2147-2155. [PMID: 25164908 DOI: 10.1093/annonc/mdu389] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND In a Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein 80 (RAP80) expression was significantly associated with outcome in Caucasian patients with nonsmall-cell lung cancer (NSCLC). The SLCG therefore undertook an industry-independent collaborative randomized phase III trial comparing nonselected cisplatin-based chemotherapy with therapy customized according to BRCA1/RAP80 expression. An analogous randomized phase II trial was carried out in China under the auspices of the SLCG to evaluate the effect of BRCA1/RAP80 expression in Asian patients. PATIENTS AND METHODS Eligibility criteria included stage IIIB-IV NSCLC and sufficient tumor specimen for molecular analysis. Randomization to the control or experimental arm was 1 : 1 in the SLCG trial and 1 : 3 in the Chinese trial. In both trials, patients in the control arm received docetaxel/cisplatin; in the experimental arm, patients with low RAP80 expression received gemcitabine/cisplatin, those with intermediate/high RAP80 expression and low/intermediate BRCA1 expression received docetaxel/cisplatin, and those with intermediate/high RAP80 expression and high BRCA1 expression received docetaxel alone. The primary end point was progression-free survival (PFS). RESULTS Two hundred and seventy-nine patients in the SLCG trial and 124 in the Chinese trial were assessable for PFS. PFS in the control and experimental arms in the SLCG trial was 5.49 and 4.38 months, respectively [log rank P = 0.07; hazard ratio (HR) 1.28; P = 0.03]. In the Chinese trial, PFS was 4.74 and 3.78 months, respectively (log rank P = 0.82; HR 0.95; P = 0.82). CONCLUSION Accrual was prematurely closed on the SLCG trial due to the absence of clinical benefit in the experimental over the control arm. However, the BREC studies provide proof of concept that an international, nonindustry, biomarker-directed trial is feasible. Thanks to the groundwork laid by these studies, we expect that ongoing further research on alternative biomarkers to elucidate DNA repair mechanisms will help define novel therapeutic approaches. TRIAL REGISTRATION NCT00617656/GECP-BREC and ChiCTR-TRC-12001860/BREC-CHINA.
Collapse
Affiliation(s)
- T Moran
- Catalan Institute of Oncology, Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain
| | - J Wei
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - M Cobo
- Medical Oncology Service, Hospital Carlos Haya, Malaga
| | - X Qian
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - M Domine
- Medical Oncology Service, Fundacion Jimenez Diaz, Madrid
| | - Z Zou
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - I Bover
- Medical Oncology Service, Hospital Son Llatzer, Palma de Mallorca
| | - L Wang
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - M Provencio
- Medical Oncology Service, Hospital Puerta de Hierro, Madrid, Spain
| | - L Yu
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - I Chaib
- Catalan Institute of Oncology, Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain
| | - C You
- Department of Oncology, Suqian General Hospital, Suqian, China
| | - B Massuti
- Medical Oncology Service, Hospital General de Alicante, Alicante, Spain
| | - Y Song
- Department of Pneumology, Jinling Hospital, Nanjing, China
| | - A Vergnenegre
- Service de Pathologie Respiratoire et d'Allergologie, CHU Limoges, Limoges, France
| | - H Lu
- Department of Pneumology, Taizhou General Hospital, Taizhou, China
| | | | - W Hu
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - G Robinet
- Service Pneumologie, CHU Brest, Brest, France
| | - J Yan
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - A Insa
- Medical Oncology Service, Hospital Clinico de Valencia, Valencia, Spain
| | - X Xu
- Department of Pneumology, Northern Jiangsu People's Hospital, Yangzhou, China
| | - M Majem
- Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain
| | - X Chen
- Department of Oncology, Huaian General Hospital, Huaian, China
| | - R de Las Peñas
- Medical Oncology Service, Hospital Provincial de Castellon, Castellon, Spain
| | - N Karachaliou
- Translational Research Unit, Dr Rosell Oncology Institute, Quiron-Dexeus University Hospital, Barcelona
| | - M A Sala
- Medical Oncology Service, Hospital de Basurto, Bilbao, Spain
| | - Q Wu
- Department of Oncology, Yixin General Hospital, Yixin, China
| | - D Isla
- Medical Oncology Service, Hospital Lozano Blesa, Zaragoza, Spain
| | - Y Zhou
- Department of Oncology, Yixin General Hospital, Yixin, China
| | - N Baize
- Department de Pneumologie, CHU Angers, Angers, France
| | - F Zhang
- Department of Oncology, Maanshan General Hospital, Maanshan, China
| | - J Garde
- Medical Oncology Service, Hospital Arnau de Vilanova, Valencia, Spain
| | - P Germonpre
- Department of Pulmonary Medicine, Antwerp University Hospital, Edegem, Belgium
| | - S Rauh
- Department of Internal Medicine and Oncology, Centre Hospitalier Emile Mayrisch, Luxembourg, Luxembourg
| | - H ALHusaini
- Oncology Center, King Faisal Cancer Center, Riyadh, Saudi Arabia
| | - M Sanchez-Ronco
- Department of Health and Medicosocial Sciences, University of Alcala, Madrid
| | | | - J J Sanchez
- Department of Preventive Medicine, Autonomous University of Madrid, Madrid
| | - C Camps
- Medical Oncology Service, Hospital General de Valencia, Valencia
| | - B Liu
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - R Rosell
- Catalan Institute of Oncology, Cancer Biology and Precision Medicine Program, Hospital Germans Trias i Pujol, Badalona; MORe Foundation, Barcelona, Spain; Cancer Therapeutic Innovation Group, New York,USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Labalette-Tiercin M, Ricordel C, Lentz PA, Delatour B, Chiforeanu D, Desrues B, Lena H. Diagnostic du sarcome de l’artère pulmonaire par voie endoscopique. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.04.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
41
|
De Latour B, Corre R, Guihaire J, Kerjouan M, Rouze S, Meunier C, Sellin M, Lena H, Verhoye JP. L’expérience rennaise des lobectomies pulmonaires par vidéothoracoscopie (VATS) sans écartement des côtes : à propos de 46 patients. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.04.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Chajon E, Bellec J, Castelli J, Kerjouan M, Corre R, Lena H, Molina S, Le Prisé E, De Crevoisier R. EP-1156: Low esophageal toxicity during simultaneous modulated accelerated radiotherapy (SMART) in locally advanced NSCLC. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31274-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
43
|
Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G, Della-Fiorentina S, Begbie S, Jennens R, Dass J, Pittman K, Ivanova N, Koynova T, Petrov P, Tomova A, Tzekova V, Couture F, Hirsh V, Burkes R, Sangha R, Ambrus M, Janaskova T, Musil J, Novotny J, Zatloukal P, Jakesova J, Klenha K, Roubec J, Vanasek J, Fayette J, Barlesi F, Bennouna-Louridi J, Chouaid C, Mazières J, Vallerand H, Robinet G, Souquet PJ, Spaeth D, Schott R, Lena H, Martinet Y, El Kouri C, Baize N, Scherpereel A, Molinier O, Fuchs F, Josten K, Manegold C, Marschner N, Schneller F, Overbeck T, Thomas M, von Pawel J, Reck M, Schuette W, Hagen V, Schneider CP, Georgoulias V, Varthalitis I, Zarogoulidis K, Syrigos K, Papandreou C, Bocskei C, Csanky E, Juhasz E, Losonczy G, Mark Z, Molnar I, Papai-Szekely Z, Tehenes S, Vinkler I, Almel S, Bakshi A, Bondarde S, Maru A, Pathak A, Pedapenki R, Prasad K, Prasad S, Kilara N, Gorijavolu D, Deshmukh C, John S, Sharma L, Amoroso D, Bajetta E, Bidoli P, Bonetti A, De Marinis F, Maio M, Passalacqua R, Cascinu S, Bearz A, Bitina M, Brize A, Purkalne G, Skrodele M, Baba A, Ratnavelu K, Saw M, Samson-Fernando M, Ladrera G, Jassem J, Koralewski P, Serwatowski P, Krzakowski M, Cebotaru C, Filip D, Ganea-Motan D, Ianuli C, Manolescu I, Udrea A, Burdaeva O, Byakhov M, Filippov A, Lazarev S, Mosin I, Orlov S, Udovitsa D, Khorinko A, Protsenko S, Chang A, Lim H, Tan Y, Tan E, Bastus Piulats R, Garcia-Foncillas J, Valdivia J, de Castro J, Domine Gomez M, Kim S, Lee JS, Kim H, Lee J, Shin S, Kim DW, Kim YC, Park K, Chang CS, Chang GC, Goan YG, Su WC, Tsai CM, Kuo HP, Benekli M, Demir G, Gokmen E, Sevinc A, Crawford J, Giaccone G, Haigentz M, Owonikoko T, Agarwal M, Pandit S, Araujo R, Vrindavanam N, Bonomi P, Berg A, Wade J, Bloom R, Amin B, Camidge R, Hill D, Rarick M, Flynn P, Klein L, Lo Russo K, Neubauer M, Richards P, Ruxer R, Savin M, Weckstein D, Rosenberg R, Whittaker T, Richards D, Berry W, Ottensmeier C, Dangoor A, Steele N, Summers Y, Rankin E, Rowley K, Giridharan S, Kristeleit H, Humber C, Taylor P. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol 2013; 24:2875-80. [DOI: 10.1093/annonc/mdt371] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Rouzé S, Flécher E, de Latour B, Meunier C, Sellin M, Lena H, Verhoye JP. [Tracheal adenoid cystic carcinoma treated by complete carinal reconstruction with the help of an ECMO: about a case]. Rev Pneumol Clin 2013; 69:144-148. [PMID: 23597633 DOI: 10.1016/j.pneumo.2013.02.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2012] [Revised: 02/26/2013] [Accepted: 02/28/2013] [Indexed: 06/02/2023]
Abstract
Primitive tumors of the trachea are rare, accounting for 0.1% of the airway tumors. Cystic adenoid carcinoma (or cylindroma) represents the second most frequent type of tracheal cancers. Histologically speaking, this tumor type is divided in three patterns: cribriform, tubular and solid; it presents a slow growth, perineural invasion and potential local recurrence and metastasis. We presented herein the case of a 56-year-old female suffering from a cystic adenoid carcinoma of the low trachea. She has been treated by carinal resection with negative airway margin and complete reconstruction, with the help of an extra corporeal membrane oxygenation (ECMO).
Collapse
Affiliation(s)
- S Rouzé
- Département de chirurgie thoracique et cardiovasculaire, CHU Pontchaillou, 2, rue Henri-le-Guilloux, 35000 Rennes, France.
| | | | | | | | | | | | | |
Collapse
|
45
|
Le Treut J, Sault MC, Lena H, Souquet PJ, Vergnenegre A, Le Caer H, Berard H, Boffa S, Monnet I, Damotte D, Chouaid C. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol 2013; 24:1548-52. [PMID: 23406729 DOI: 10.1093/annonc/mdt009] [Citation(s) in RCA: 101] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The optimal treatment of large-cell neuroendocrine carcinoma (LCNEC) of the lung remains unclear. Here, our primary objective was to assess the efficacy of cisplatin-etoposide doublet chemotherapy in advanced LCNEC. Accuracy of the pathological diagnosis and treatment toxicity were assessed as secondary objectives. PATIENTS AND METHODS Prospective, multicentre, single-arm, phase II study with a centralised review of treatment-response and pathological data. Patients had untreated performance status (PS) 0/1 stage IV/IIIB LCNEC and received cisplatin (80 mg/m22 d1) and etoposide (100 mg/m22 d1-3) every 21 days. RESULTS Eighteen centres included 42 patients (mean age, 59 ± 9 years; 69% men; median of four cycles/patient). At least one grade-3/4 toxicity occurred in 59% of patients (neutropaenia, thrombocytopaenia, and anaemia in 32%, 17%, and 12%, respectively). The median progression-free survival (PFS) and overall survival (OS) were 5.2 months (95% confidence interval, CI, 3.1-6.6) and 7.7 months (95% CI, 6.0-9.6), respectively. The centralised pathologist review reclassified 11 of 40 (27.5%) patients: 9 as small-cell lung cancer, 1 as undifferentiated non-small-cell lung cancer, and 1 as atypical carcinoid. Survival data were not significantly changed by excluding the reclassified patients. CONCLUSIONS The pathological diagnosis of LCNEC is difficult. The outcomes of advanced LCNEC treated with cisplatin-etoposide doublets are poor, similar to those of patients with advanced small-cell lung carcinoma (SCLC).
Collapse
Affiliation(s)
- J Le Treut
- Department of Pneumology, Aix en Provence, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Thiberville L, Gounant V, Salaun M, Febvre M, Vergnon JM, Jounieaux V, Fournier C, Lachkar S, Hermant C, Raspaud C, Quantin X, Quiot JJ, Molard A, Dayen C, Marquette C, Lena H, Zalcman G, Chouaid C. Évaluation de l’écho-endoscopie bronchique dans la stratégie de prise en charge des cancers du poumon : résultats de l’étude française multicentrique EVIEPEB2. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Rouze S, de Latour B, Jouneau S, Kerjouan M, Lentz PA, Belleguic C, Lena H, Sellin M, Verhoye JP. Carcinome adénoïde kystique trachéal traité par reconstruction complète de la carène : à propos d’un cas. Rev Mal Respir 2012. [DOI: 10.1016/j.rmr.2012.10.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
48
|
Perotin JM, Jeanfaivre T, Thibout Y, Jouneau S, Lena H, Dutau H, Ramon P, Lorut C, Noppen M, Vergnon JM, Vallerand H, Merol J, Marquette CH, Lebargy F, Deslee G. Traitement endoscopique des sténoses trachéales idiopathiques. Rev Mal Respir 2012. [DOI: 10.1016/j.rmr.2011.10.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
49
|
Edeline J, Lena H, Cvitkovic E, Penel N, Reyderman L, Edwards G, Law K, Delord J, Lesimple T. 1244 POSTER An Open-Label, Multicenter, Single Arm QT Interval Prolongation Study of Eribulin Mesylate in Patients With Advanced Solid Tumours. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70856-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
50
|
Kerjouan M, Jouneau S, Lena H, Luraine R, Desrues B, Delaval P. Sarcoïdose pulmonaire apparue sous étanercept. Rev Mal Respir 2011; 28:360-4. [DOI: 10.1016/j.rmr.2010.08.018] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2010] [Accepted: 08/31/2010] [Indexed: 10/18/2022]
|